Abstract
The response of intramuscularly growing KHT sarcomas to the chemotherapeutic agent (1-(2-cloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) alone or simultaneously with the chemical radio-sensitizer misonidazole (MISO) was assessed using either a tumour growth-delay assay or an in vivo-in vitro tumour-excision assay. Median tumour growth delay following the combination of 20 mg/kg CCNU and either 0.5 or 1.0 mg/g MISO was 19.5 and 21.5 days, compared to 10 days for this CCNU dose alone. A similar degree of enhanced tumour response by MISO (factor of approximately 2 in tumour growth delay) was seen in RIF-1 tumours treated with 20 mg/kg CCNU plus 1.0 mg/g MISO. Clonogenic cell-survival studies with KHT sarcomas demonstrated that MISO at doses of 0.25, 0.5 or 1.0 mg/g given simultaneously with a range of CCNU doses produced dose-modifying factors (DMFs) of 1.9, 2.1 and 2.4 respectively. Normal tissue toxicity assessed by an LD50/7 assay led to DMFs of 1.2 and 1.4 for CCNU doses combined with 0.5 and 1.0 mg/g MISO. Thus in this animal tumour model the combination of CCNU and MISO appears to lead to a potential gain by a factor of approximately 1.7.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Siemann, D. In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer 43, 367–377 (1981). https://doi.org/10.1038/bjc.1981.57
Issue Date:
DOI: https://doi.org/10.1038/bjc.1981.57
- Springer Nature Limited
This article is cited by
-
Clinical pharmacokinetics of oral CCNU (Lomustine)
Cancer Chemotherapy and Pharmacology (1985)
-
Mitomycin-C plus metronidazole in advanced carcinoma of the breast
Breast Cancer Research and Treatment (1985)
-
Treatment of malignant gliomas in adults with BCNU plus metronidazole
Journal of Neuro-Oncology (1984)